Ironwood director granted 63,481 shares

Currie Mark G reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Currie Mark G reported acquisition or exercise transactions in this Form 4 filing.

IRONWOOD PHARMACEUTICALS INC director Mark G. Currie received a grant of 63,481 shares of Class A common stock as restricted stock, awarded at no cash cost to him as part of director compensation.

According to the company’s non-employee director compensation policy, this restricted stock vests in full on the date immediately before the next year’s annual meeting of stockholders. After this award, Currie directly holds 676,900 shares of Ironwood common stock.

Insider Trade Summary

Grant/Award: 63,481 shares

Grant/Award 1 txn

Insider Currie Mark G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	63,481	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 676,900 shares (Direct)

Footnotes (1)

1. F1. The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.

Key Figures

Restricted stock grant: 63,481 shares Grant price per share: $0.00 per share Total shares after grant: 676,900 shares

3 metrics

Restricted stock grant 63,481 shares Class A Common Stock awarded to director Mark G. Currie

Grant price per share $0.00 per share Stated transaction price for restricted stock award

Total shares after grant 676,900 shares Currie’s direct holdings following the transaction

Key Terms

restricted stock, Second Amended and Restated Non-employee Director Compensation Policy, annual meeting of stockholders

3 terms

restricted stock financial

"The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Second Amended and Restated Non-employee Director Compensation Policy financial

"granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024"

annual meeting of stockholders financial

"vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ironwood Pharmaceuticals (IRWD) director Mark G. Currie report in this Form 4?

Director Mark G. Currie reported receiving 63,481 shares of Ironwood Class A common stock as restricted stock. The award was granted at no cash cost under the company’s non-employee director compensation policy and is part of his board compensation package.

How many Ironwood (IRWD) shares does Mark G. Currie own after this grant?

After the restricted stock grant, Mark G. Currie directly holds 676,900 shares of Ironwood Class A common stock. This figure reflects his total direct ownership immediately following the award disclosed in the Form 4 filing with the SEC.

What are the vesting terms of Mark G. Currie’s new Ironwood restricted stock?

The 63,481 restricted shares granted to Mark G. Currie vest in full on the date immediately preceding Ironwood’s annual meeting of stockholders for the next calendar year. Until vesting, the shares are subject to the restricted stock conditions described in the company’s policy.

Was Mark G. Currie’s Ironwood share grant a market purchase or sale?

The transaction was a grant of restricted stock, not a market purchase or sale. Currie acquired 63,481 shares at a stated price of $0.00 per share as compensation under Ironwood’s Second Amended and Restated Non-employee Director Compensation Policy.

What compensation policy governed Mark G. Currie’s Ironwood restricted stock award?

The award was granted under Ironwood’s Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024. This policy outlines how non-employee directors are compensated, including equity grants such as the restricted stock disclosed here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 04:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Currie Mark G

(Last) (First) (Middle)

C/O IRONWOOD PHARMACEUTICALS, INC.

100 SUMMER STREET, SUITE 2300

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IRONWOOD PHARMACEUTICALS INC [ IRWD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/16/2026		A(1)		63,481	A	$0	676,900	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.

	/s/ Amir Vitale, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)